vendredi 26 avril 2019

Onco Actu du 26 avril 2019

         Pour info : Onco Actu interrompt sa parution pendant une semaine.
 

1. BIOLOGIE



Researchers reveal key to targeting dormant cancer cells [Garvan Institute]











Colon Cancer Biology, Treatment Clues Found in Proteogenomic Analysis [Genome Web]











Colon cancer proteins, genes uncover potential treatments [Baylor College of Medicine]











1.4 BIOLOGIE - TECHNOS



Ovarian Cancer Organoids [ESMO]











4.10 DÉP., DIAG. & PRONO. - POUMON



Rates of Physician-Patient Discussions About Lung Cancer Screening Very Low and Declining [AACR]











Screening for lung cancer is a controversial idea [The Economist]











4.9 DÉP., DIAG. & PRONO. - SEIN



Six Factors May Predict Invasive Breast Cancer Recurrence after Ductal Carcinoma in Situ Diagnosis [AACR]











5. TRAITEMENTS



Chemotherapy or not? [Case Western Reserve University]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Fishing for cures: New zebrafish model identifies drugs that kill pediatric cancer cells [Mass. General Hospital]











Researchers demonstrate arsenic-based therapy can reverse drug tolerance in acute myeloid leukemia [Beth Israel Deaconess Medical Center]











5.12 IMMUNOTHÉRAPIES



Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers [NCI]










5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks [Fierce Biotech]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline [Mateon]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop [Fierce Pharma]










Another one of Bristol-Myers’ PD-1/CTLA-4 combo studies bites the dust [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Bristol arms itself for kidney-cancer fight as Keytruda threatens Opdivo's share [Fierce Pharma]











Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Merck]










5.15 ESTRO



Early, hormone-driven breast cancer is less likely to recur if treated with radiotherapy [ESTRO]











5.2 PHARMA



Lilly to withdraw FDA-approved cancer drug after clinical failure [Biopharma Dive]











Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market [Lilly]











As it takes Lartruvo off the shelves, Lilly is setting up program to provide drug access to current patients [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Pharma’s Secret to Lobbying for Higher Drug Prices? [Bloomberg]










6.1 OBSERVATION



One in six people dying of lung cancer in UK are non-smokers, experts say [The Guardian]










6.7.3 DMP



Electronic health records may compromise safety for chemotherapy patients [University of Michigan]